MARK YODER: Open Payments
NPI 1235597048 · WOOSTER, OH. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,475 in 57 payments from 17 companies in 2025. Trend: 2023 $2,130 · 2024 $2,079 · 2025 $1,475
Food & beverage: $1,460Education: $15
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $451 |
| Alkermes, Inc. | 7 | $202 |
| Neurocrine BioSciences, Inc. | 4 | $162 |
| Kerecis Limited | 2 | $161 |
| Novo Nordisk Inc | 6 | $151 |
| Xeris Pharmaceuticals, Inc. | 3 | $97 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Janssen Pharmaceuticals, Inc | 1 | $24 |
| Organon LLC | 1 | $24 |
Products named: VRAYLAR, QULIPTA, INGREZZA, Kerecis SurgiClose, VIVITROL, Ozempic, GVOKE HYPOPEN, UBRELVY.
Industry payments across OH — which companies pay providers there.
